Please assess the completion status of the following clinical trial:

Trial Title: A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Total testosterone level \<300 nanogram per deciliter (ng/dL) \[10.4 nanomole per Liter (nmol/L)\] at each of 2 screening visits~* At least 1 symptom of testosterone deficiency, which must include decreased energy or decreased sexual drive~* Prostate Specific Antigen (PSA) \<4 nanogram per milliliter (ng/ml) at screening~Exclusion Criteria:~* Sexual partner who is or becomes pregnant at any time during the study~* Use of long-acting intramuscular (IM) testosterone undecanoate or testosterone pellets in the 6-month period prior to screening~* Body Mass Index (BMI) \>37 kilogram per square meter (kg/m\^2) at screening~* Severe lower urinary tract symptoms and/or significant prostate enlargement~* Prolactin lab test result of \>30 ng/mL at screening~* Hemoglobin A1c (HbA1c) \>11% at screening~* Hematocrit ≥50% (\>54% at elevated altitude) at screening~* Current use of any medications, herbal, and/or nutritional supplements that can interfere with testosterone~* Dermatologic condition in underarm area that might interfere with testosterone absorption (for example, eczema) or be exacerbated by topical testosterone replacement therapy~* Currently receiving treatment with cancer chemotherapy or antiandrogens~* Chronic use of systemic glucocorticoids (use for \>14 days within the 3 months prior to screening); use of non-testosterone anabolic steroids within 12 months prior to screening~* Competitive athletes involved in a sport in which they may be screened for anabolic steroids~* History of use of estrogenizing agents within 12 months prior to screening~* History of luteinizing hormone-releasing hormone antagonist or agonist treatment in the last 6 months prior to screening~* History of clomiphene or other anti-estrogen treatment in the 3 months prior to screening~* Use of finasteride within 3 months prior to screening, or use of dutasteride within 6 months prior to screening~* Current use of warfarin or phenprocoumon~* History of frequent opioid use: \>1 time/week during any week within 30 days prior to screening~* Current use of dopamine receptor agonists (cabergoline, pergolide, bromocriptine)~* Have a history of significant central nervous system injuries or disease (including stroke, spinal cord injury, or multiple sclerosis) within 6 months prior to screening~* Systolic blood pressure \>170 or \<90 millimeter of mercury (mm Hg) or diastolic blood pressure \>100 or \<50 mm Hg at screening or a history of malignant hypertension~* History of unstable angina as defined by Braunwald Classification of Unstable Angina or angina occurring during sexual intercourse in the last 6 months~* History of any of the following coronary conditions within 90 days of screening: myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention (angioplasty or stent placement)~* Have any supraventricular arrhythmia with an uncontrolled ventricular response \[mean heart rate \>100 beats per minute (bpm)\] at rest, or have any history of spontaneous or induced sustained ventricular tachycardia (heart rate \>100 bpm for ≥30 seconds), or use of an automatic internal cardioverter-defibrillator~* Have a history of sudden cardiac arrest~* Exhibit any evidence of congestive heart failure \[New York Heart Association (NYHA) Class 2 or above\], within 6 months prior to screening~* Have had a new, significant cardiac conduction defect within 90 days prior to screening~* Clinical suspicion (or history) of prostate cancer during digital rectal examination at screening~* Known or suspected breast cancer (or history of breast cancer) or other active cancer (with the exception of nonmelanotic skin cancer)~* Exhibit evidence of severe renal impairment \[creatinine clearance \<30 milliliter per minute (mL/min) as determined by the Cockcroft-Gault formula\] at screening~* Exhibit a history of severe liver disease or clinical evidence of hepatic impairment at screening~* Have a history of human immunodeficiency virus (HIV) infection~* Severe sleep apnea~* Untreated hypothyroidism, hypercortisolism or other significant endocrinopathy (other than hypogonadism) that contributes to symptoms of low energy or fatigue

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Solution (Type: PLACEBO_COMPARATOR): Placebo Solution applied topically once daily for 12 weeks.
- Testosterone Solution (Type: EXPERIMENTAL): Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).